文献速递类风湿关节炎

基线及早期C反应蛋白变化对托珠单抗治疗类风湿关节炎临床结局的预测意义

Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
PubMed 文献 · Ann Rheum Dis · 2020-05-05

研究分析了1126个托珠单抗治疗早期RA疗程、250个利妥昔单抗和249个甲氨蝶呤治疗 established RA 疗程的数据,比较基线CRP及24周内早期变化与CDAI疾病活动度的关系。结果显示托珠单抗组基线CRP越高越可能达到CDAI缓解,而利妥昔单抗和甲氨蝶呤组则相反;托珠单抗治疗4周内CRP下降幅度大者更易缓解,早期CRP无应答提示难以达标。

要点

  • 托珠单抗治疗早期RA时,基线CRP水平越高越可能达到CDAI缓解。
  • 利珠单抗和甲氨蝶呤治疗established RA时,基线CRP与缓解呈负相关。
  • 托珠单抗治疗4周内CRP下降幅度大者24周缓解率更高,早期无应答提示预后不佳。

核心结论

  • 基线CRP对托珠单抗治疗达到治疗目标呈正相关,但对利珠单抗和甲氨蝶呤呈负向预测。
  • 托珠单抗治疗早期CRP无应答者达到临床缓解的机会较低。

研究设计与样本

  • 分析1126个托珠单抗治疗早期RA疗程、250个利珠单抗和249个甲氨蝶呤治疗established RA疗程的数据。
  • 比较基线CRP及24周随访期间CDAI变化,并用另一项早期RA托珠单抗试验数据验证结果。

主要发现

  • 托珠单抗组CRP水平在4周内平均下降74%。
  • 托珠单抗组24周达到CDAI缓解者基线CRP最高,高疾病活动度者基线CRP最低;利珠单抗和甲氨蝶呤组该关联方向相反。
  • 托珠单抗组24周缓解者第4周CRP下降幅度最大,早期CRP无应答提示未达到临床治疗目标的风险(p=0.038)。

临床怎么用

  • 基线CRP及早期CRP变化可一定程度帮助预估RA患者治疗成功的可能性。
  • 托珠单抗治疗早期CRP无应答者需警惕难以达到临床缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis (RA) is characterised by clinical joint swelling and elevation of acute phase reactant levels, typically measured by the C-reactive protein (CRP). Clinical and inflammatory responses are usually concordant, except for inhibition of IL-6, which often disproportionally reduces the CRP due to direct inhibition of its hepatic production. We investigated whether pre-treatment CRP is a useful marker that can guide a preferential treatment choice towards IL-6 inhibition. METHODS: Data of 1126 treatment courses with tocilizumab (TCZ; early RA), 250 courses of rituximab (RTX; established RA) and 249 courses of methotrexate (MTX; established RA) were analysed. We compared clinical disease activity index (CDAI) values and change along 24 weeks' follow-up to CRP values at baseline or its early change. We validated the results using data from a separate TCZ trial in early RA. RESULTS: CRP levels in the TCZ group on average dropped by 74% within 4 weeks. Patients who attained CDAI remission at 24 weeks on TCZ had the highest baseline CRP levels while patients in high disease activity had the lowest; this association was reverse in the RTX and MTX groups. TCZ patients who achieved remission at 24 weeks showed the largest reductions of CRP levels by week 4 compared with those reaching higher disease activity states. Early CRP non-response was indicative of a risk of not achieving clinical treatment goals (p=0.038). CONCLUSION: Baseline CRP appears to have a positive association with reaching the therapeutic target on TCZ treatment, but is a negative predictor for RTX and MTX. Patients on TCZ without an early CRP response have a lower chance of achieving remission. CRP and its early course may inform, to some extent, the estimation of potential therapeutic success in patients with RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Shafran IH, Alasti F, Smolen JS, et al. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2020. PMID: 32371387. doi:10.1136/annrheumdis-2019-215987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。